September 13, 2024 04:49 AM EDTUpdated 07:12 AM
R&D

Neu­ro­crine culls Phase 2 neu­ropsych med af­ter fail­ing to val­i­date ear­li­er da­ta

Max Bayer

Pharma Reporter

Neu­ro­crine is halt­ing fur­ther de­vel­op­ment of lu­vadax­i­s­tat af­ter it failed to im­prove cog­ni­tive im­pair­ment in pa­tients with schiz­o­phre­nia in a mid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times